DELRAY BEACH, Fla.--(BUSINESS WIRE)--VeriChip Corporation (the “Company” or “VeriChip”) (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, announced today that John D. Halamka, MD, MS, has joined the Company’s Medical Advisory Board as well as the joint committee formed by VeriChip and Digital Angel Corporation to design and develop a working, implantable glucose microchip to determine glucose levels in the bodies of animals and humans. Dr. Halamka serves as the Chief Information Officer of Harvard Medical School, Chief Information Officer of Beth Israel Deaconess Medical Center, Chief Information Officer of the Harvard Clinical Research Institute, and an Associate Professor of Emergency Medicine at Harvard Medical School. Dr. Halamka also serves on other nationally recognized boards including Google’s Health Advisory Council. He will serve as an unpaid advisor on privacy, security and standards issues, as well as strategy and future applications of the VeriChip RFID implantable microchip technology.
